Author of

• 12544

  +

  P3.08 - Poster Session 3 - Radiotherapy (ID 199)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Radiation Oncology + Radiotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12546

    +

    P3.08-002 - An evidence-based estimation of survival and local control benefit of radiotherapy for lung cancer (ID 271)

    09:30 - 09:30  |  Author(s): M. Barton
    • Abstract

    Background
    Evidence-based Radiotherapy utilisation benchmarks [Delaney G et al, Cancer 2003] have been used as the basis for planning radiotherapy services both nationally and internationally. These utilisation models have been further expanded to estimate the benefit for each radiotherapy indication in individual cancer sites using evidence-based approach [Shafiq J et al, Radiotherapy and Oncology 2007].

    Methods
    Our study aimed at estimating the benefit of definitive or adjuvant radiotherapy to overall survival and local control of lung cancer patients if the entire lung cancer population are treated according to evidence-based treatment guidelines. The optimal radiotherapy utilization model previously reported for small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) was extended to incorporate overall survival and local control benefit from radiotherapy (radiotherapy vs no radiotherapy, radiotherapy and concurrent chemotherapy vs radiotherapy alone) from published data (1990-2010). Palliative benefits were not considered.

    Results
    The overall gains in 5-year local control and survival were 11% (95% CI 9.5%-12.3%) and 5% (95% CI 3.6%-6.7%) respectively if optimal radiotherapy was applied for all lung cancer patients. The optimal gains for all lung cancer from concurrent chemotherapy and radiotherapy over radiotherapy alone were 5% (95% CI 1.7%-7.6%) for local control and 4% (95% CI 1.0%-6.0%) for survival. The overall local control benefit for radiotherapy including concurrent chemotherapy for SCLC and NSCLC were 10% and 17%; 5 year survival benefit proportions were: SCLC 2% and NSCLC 10%.

    Conclusion
    Our model provides a quantitative estimate of benefit of curative radiotherapy for lung cancer at the population level if evidence-based guidelines were applied. The model predicted that guidelines-recommended application of radiotherapy treatment could save 900 extra lives per 10 000 cases of lung cancer for up to 5 years and prevent 1600 local recurrences in that period.